• Japanese
  • Korean
  • Chinese
Cover Image

Global Vaccine Market Forecast to 2017

Abstract

Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players.

Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases.

The report, "Global Vaccine Market Forecast to 2017" provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US$ 27.3 bllion in 2012, is expected to grow at a CAGR of around 12% during 2012-2017.

In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.

The study further delves into the business dynamics of the major players in industry. To provide a thorough understanding of a company's business model, the company's current and historical financials have been analyzed. Moreover, our team has also analyzed each company's strengths and weaknesses along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition. This will help the reader to gain a deeper insight into each key market player.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Vaccine Market Outlook to 2017

4. Major Vaccines: Current and Future Market Analysis

  • 4.1 Pneumococcal
  • 4.2 Influenza
  • 4.3 Cancer
  • 4.4 Polio
  • 4.5 Varicella
  • 4.6 Rotavirus
  • 4.7 Meningococcal
  • 4.8 DTP
  • 4.9 Hepatitis
  • 4.10 Measles, Mumps, and Rubella (MMR)
  • 4.11 Japanese Encephalitis
  • 4.12 Tuberculosis
  • 4.13 Malaria
  • 4.14 Rabies
  • 4.15 Typhoid
  • 4.16 HIV

5. Key Geographical Markets

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China
  • 5.5 India
  • 5.6 Brazil

6. Competitive Landscape

  • 6.1 GSK
  • 6.2 Sanofi-Pasteur
  • 6.3 Pfizer
  • 6.4 Merck
  • 6.5 Novartis
  • 6.6 Emergent Biosolutions
  • 6.7 AstraZeneca Plc.
  • 6.8 Baxter International Inc.
  • 6.9 BioCSL (CSL Biotherapies)
  • 6.10 Dendreon Corporation
  • 6.11 Takeda Pharmaceutical Company Limited
  • 6.12 Crucell

List of Figures:

  • Figure 3-1: Global - Vaccine Market (Billion US$), 2012-2017
  • Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011
  • Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2012-2017
  • Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2012-2017
  • Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2012-2017
  • Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2012-2017
  • Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2012-2017
  • Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2012-2017
  • Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2012-2017
  • Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
  • Figure 4-10: Global - Number of Ntetanus Incidences by Region (2009 & 2010)
  • Figure 4-11: Global - Number of Ttetanus Incidences by Region (2009 & 2010)
  • Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
  • Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2012-2017
  • Figure 4-14: Global - Hepatitis Vaccine Market (Million US$), 2012-2017
  • Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
  • Figure 4-16: Global - Number of Mumps Incidences by Region ('000), 2009 & 2010
  • Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
  • Figure 4-18: Global - MMR Vaccine Market (Million US$), 2012-2017
  • Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2012-2017
  • Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
  • Figure 5-1: Global - Vaccine Market by Region (%), 2012
  • Figure 5-2: Global - Vaccine Market by Region (%), 2017
  • Figure 5-3: US - Vaccine Market (Billion US$), 2012-2017
  • Figure 5-4: Europe - Vaccine Market (Billion US$), 2012-2017
  • Figure 5-5: Japan - Vaccine Market (Billion US$), 2012-2017
  • Figure 5-6: China - Vaccine Market (Billion US$), 2012-2017
  • Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2010)
  • Figure 5-8: India - Vaccine Market (Billion US$), 2012-2017
  • Figure 5-9: Brazil - Vaccine Market (Billion US$), 2012-2017
  • Figure 6-1: Global - Share of Key Players in Vaccine Market (2012)
  • Figure 6-2: GSK - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-3: GSK - Vaccine Revenue Breakup by Product (%), 2012
  • Figure 6-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2012
  • Figure 6-6: Pfizer - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2012
  • Figure 6-8: Merck - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2012
  • Figure 6-10: Novartis - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2012
  • Figure 6-12: Baxter International - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-13: BioCSL - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2012
  • Figure 6-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010

List of Tables:

  • Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
  • Table 4-2: Key Pneumococcal Vaccines in Pipeline
  • Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
  • Table 4-4: Key Influenza Vaccines in Pipeline
  • Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
  • Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
  • Table 4-7: Key Cancer Vaccines in Pipeline
  • Table 4-8: Polio Vaccine Market - Key Players and Vaccines
  • Table 4-9: Key Polio Vaccines in Pipeline
  • Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
  • Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
  • Table 4-12: Key Rotavirus Vaccines in Pipeline
  • Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
  • Table 4-14: Key Meningococcal Vaccines in Pipeline
  • Table 4-15: DTP Vaccine Market - Key Players and Vaccines
  • Table 4-16: Key DTP Vaccines in Pipeline
  • Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
  • Table 4-18: Key Hepatitis Vaccines in Pipeline
  • Table 4-19: MMR Vaccine Market - Key Players and Vaccines
  • Table 4-20: Key MMR Vaccines in Pipeline
  • Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
  • Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
  • Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
  • Table 4-24: Key Tuberculosis Vaccines in Pipeline
  • Table 4-25: Key Malaria Vaccines in Pipeline
  • Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
  • Table 4-27: Key Rabies Vaccines in Pipeline
  • Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
  • Table 4-29: Key Typhoid Vaccines in Pipeline
  • Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
  • Table 4-31: Key HIV Vaccines in Pipeline
  • Table 5-1: China - Vaccine Classification
  • Table 5-2: China - Annual Pediatric Vaccine Doses Requirement (Million Doses)
  • Table 6-1: GSK - Vaccines Portfolio
  • Table 6-2: GSK - Vaccines in Pipeline
  • Table 6-3: GSK - Strengths and Weaknesses
  • Table 6-4: Sanofi-Pasteur - Vaccines Portfolio
  • Table 6-5: Sanofi-Pasteur - Vaccines in Pipeline
  • Table 6-6: Sanofi-Pasteur - Strengths and Weaknesses
  • Table 6-7: Pfizer - Vaccines Portfolio
  • Table 6-8: Pfizer - Vaccines in Pipeline
  • Table 6-9: Pfizer - Strengths and Weaknesses
  • Table 6-10: Merck - Vaccines Portfolio
  • Table 6-11: Merck - Vaccines in Pipeline
  • Table 6-12: Merck - Strengths and Weaknesses
  • Table 6-13: Novartis - Vaccines Portfolio
  • Table 6-14: Novartis - Vaccines in Pipeline
  • Table 6-15: Novartis - Strengths and Weaknesses
  • Table 6-16: Emergent Biosolutions - Vaccines Portfolio
  • Table 6-17: Emergent Biosolutions - Vaccines in Pipeline
  • Table 6-18: Emergent Biosolutions - Strengths and Weaknesses
  • Table 6-19: AstraZeneca - Vaccines Portfolio
  • Table 6-20: AstraZeneca - Vaccines in Pipeline
  • Table 6-21: AstraZeneca - Strengths and Weaknesses
  • Table 6-22: Baxter International - Vaccines Portfolio
  • Table 6-23: Baxter International - Vaccines in Pipeline
  • Table 6-24: Baxter International - Strengths and Weaknesses
  • Table 6-25: BioCSL - Vaccines Portfolio
  • Table 6-26: BioCSL - Strengths and Weaknesses
  • Table 6-27: Dendreon Corporation - Vaccines Portfolio
  • Table 6-28: Dendreon Corporation - Vaccines in Pipeline
  • Table 6-29: Dendreon Corporation - Strengths and Weaknesses
  • Table 6-30: Takeda Pharmaceutical - Vaccines Portfolio
  • Table 6-31: Takeda Pharmaceutical - Vaccines in Pipeline
  • Table 6-32: Takeda Pharmaceutical - Strengths and Weaknesses
  • Table 6-33: Crucell - Vaccines Portfolio
  • Table 6-34: Crucell - Vaccines in Pipeline
  • Table 6-35: Crucell - Strengths and Weaknesses
Show More
Pricing
Get Notified
Email me when related reports are published